SCHEMBL4698636

SCHEMBL4698636

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1Nc1nc(-c2ccncc2)nc2c1cnn2C

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 12/20 0.76
BTK Q06187 4/20 0.76
ESYT2 A0FGR8 2/20 0.76
NBAS A2RRP1 2/20 0.76
CNOT1 A5YKK6 2/20 0.76
TBKBP1 A7MCY6 2/20 0.76
AGPS O00116 2/20 0.76
MYO1F O00160 2/20 0.76
SNAP23 O00161 2/20 0.76
AP3B1 O00203 2/20 0.76
PSMD12 O00232 2/20 0.76
BMPR1B O00238 2/20 0.76
PGRMC1 O00264 2/20 0.76
CLIC1 O00299 2/20 0.76
CDC7 O00311 2/20 0.76
IPO5 O00410 2/20 0.76
PLK4 O00444 2/20 0.76
COXFA4 O00483 2/20 0.76
NOP56 O00567 2/20 0.76
DDX3X O00571 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4697696 0.94 BRAF (0.86) BRAFBTKESYT2NBASCNOT1
SCHEMBL4697866 0.92 BRAF (0.89) BRAFBTKESYT2NBASCNOT1
SCHEMBL4696222 0.89 BRAF (0.72) BRAFBTKESYT2NBASCNOT1
SCHEMBL22024695 0.88 BRAF (0.86) BRAFBTKESYT2NBASCNOT1
SCHEMBL29358745 0.86 ABL1 (1.00) BRAFBTKESYT2NBASCNOT1
SCHEMBL4699731 0.86 ABL1 (1.00) BRAFBTKESYT2NBASCNOT1
SCHEMBL29380618 0.86 ABL1 (1.00) BRAFBTKESYT2NBASCNOT1
SCHEMBL23092285 0.86 BRAF (0.86) BRAFBTKESYT2NBASCNOT1
SCHEMBL22024567 0.86 BRAF (0.81) BRAFBTKESYT2NBASCNOT1
SCHEMBL29688472 0.86 BRAF (0.86) BRAFBTKESYT2NBASCNOT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963327-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS Novartis AG (CH) 2008-09-03 EP claimed
WO-2007062805-A1 3-(SUBSTITUTED AMINO)-PYRAZOLO[3,4-d]PYRIMIDINES AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-07 WO claimed
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors HOLZER PHILIPP 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275054-A1 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors EPHB3, EPHB2, EPHB1 BRAF 42/4885BTK 214/4885ESYT2 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.